DR5 antibody [DR5-01-1] (PE)
GTX80180
Overview
- SupplierGeneTex
- Product NameDR5 antibody [DR5-01-1] (PE)
- Delivery Days Customer9
- Antibody SpecificityThis antibody recognizes an extracellular domain of TRAIL-R2 (DR5).
- ApplicationsFlow Cytometry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDDR5-01-1
- Concentration0.1 mg/ml
- ConjugateRPE
- Gene ID8795
- Target nameTNFRSF10B
- Target descriptionTNF receptor superfamily member 10b
- Target synonymsapoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; DR5; Fas-like protein; KILLER; KILLER/DR5; p53-regulated DNA damage-inducible cell death receptor(killer); TNF-related apoptosis-inducing ligand receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; ZTNFR9
- HostMouse
- IsotypeIgG1
- Scientific DescriptionThe protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene. [provided by RefSeq, Mar 2009]
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B more Efficiently than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors. ?rtykov ?? et al., 2020 Apr 30, Cancers (Basel)Read more
- Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. Yagolovich AV et al., 2020 Apr, Transl OncolRead more